Reduced Silent Occlusions with a Novel Catheter Infusion Set (BD FlowSmart): Results from Two Open-Label Comparative Studies

Diabetes Technology and Therapeutics

Volumn 18, Issue 3, 2016, Pages 136-143

  Gibney, Michael ^a   Xue, Zhenyi ^a   Swinney, Monica ^b   Bialonczyk, Damian ^a,c   Hirsch, Laurence ^a  

^a BD Technologies   (United States)

^b BD Research and Development   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DILUENT; INSULIN LISPRO; POLYMER;

ADULT; ARTICLE; CATHETER INFUSION SET; CATHETER OCCLUSION; COMPARATIVE STUDY; CONTROLLED STUDY; ERYTHEMA; FEMALE; HUMAN; INFUSION SYSTEM; INSULIN INFUSION; INSULIN PUMP; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRESSURE; PRIORITY JOURNAL; SILENT CATHETER OCCLUSION; ADOLESCENT; ADVERSE EFFECTS; AGED; CATHETER OBSTRUCTION; CATHETERIZATION; DEVICE FAILURE; DEVICES; EDUCATION; EQUIPMENT DESIGN; INDWELLING CATHETER; MATERIALS TESTING; MIDDLE AGED; NEW JERSEY; NURSING; NURSING DISCIPLINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TOTAL QUALITY MANAGEMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CATHETER OBSTRUCTION; CATHETERIZATION; CATHETERS, INDWELLING; EQUIPMENT DESIGN; EQUIPMENT FAILURE; FEMALE; HUMANS; INSULIN INFUSION SYSTEMS; MALE; MATERIALS TESTING; MIDDLE AGED; NEW JERSEY; PILOT PROJECTS; QUALITY IMPROVEMENT; SPECIALTIES, NURSING; YOUNG ADULT;

EID: 84962589803     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2015.0342     Document Type: Article

References (19)

1. Pickup JC, Keen H, Parsons JA, et al.: Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978;1:204-207.
2. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R: Insulin pump therapy: A meta-analysis. Diabetes Care 2003; 26:1079-1087.
3. Heinemann L: Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements? J Diabetes Sci Technol 2009;3:1490-1500.
4. Bergenstal RM, Tamborlane WV, Ahmann A, et al.: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320.
5. Garg SK, Voelmle MK, Beatson CR, et al.: Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy. Diabetes Care 2011;34:574-579.
6. Heinemann L, Krinelke L: Insulin infusion set: The Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol 2012;6:954-964.
7. Pickup JC, Yemane, N, Brackenridge, A, et al.: Nonmetabolic complications of continuous subcutaneous insulin infusion: A patient survey. Diabetes Technol Ther 2014;16: 145-149.
8. Heinemann L, Flemming GA, Petrie JR, et al.: Insulin pump risks and benefits: A clinical appraisal of pump safety standards, adverse event reporting, and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Technology Working Group. Diabetes Care 2015; 38:716-722.
9. van Bon AC, Bode BW, Sert-Langeron C, et al.: Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diabetes Technol Ther 2011;13:607-614.
10. Keith S, McVey E, Pettis RJ: High sensitivity occlusion detection using fluid pressure monitoring during basal insulin infusion. Diabetes 2013;62(suppl 1):A249-A250.
11. van Bon AC, Dragt D, deVries JH: Significant time until catheter occlusion alerts in currently marketed insulin pumps at two basal rates. Diabetes Technol Ther 2012;14: 447-448.
12. Bolick N, Morel D, Gerth S, et al.: Reduction of silent occlusion occurrence during continuous subcutaneous insulin infusion [abstract]. Diabetes Technol Ther 2015;17(Suppl 1): A35.
13. Bolick N, Morel D, Alarcon J, et al.: In vivo flow evaluation and correlation to insulin pharmacokinetics of continuous subcutaneous insulin infusion sets [abstract]. Diabetes 2015;64(Suppl 1):A274-A275.
14. Cope JU, Samuels-Reid JH, Morrison AE: Pediatric use of insulin pump technology: A retrospective study of adverse events in children ages 1-12 years. J Diabetes Sci Technol 2012;6:1053-1059.
15. Patel PJ, Benasi K, Ferrari, G, et al.: Randomized trial of infusion set function: steel versus Teflon. Diabetes Technol Ther 2014;16:15-19.
16. Renard E, Guerci B, Leguerrier AM, et al.: Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Diabetes Technol Ther 2010;12:769-773.
17. Ponder SW, Skyler JS, Kruger DF, et al.: Unexplained hyperglycemia in continuous subcutaneous insulin infusion: evaluation and treatment. Diabetes Educ 2008;34:327-333.
18. Thethi TK, Rao A, Kawji H, et al.: Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications 2010;24:73-78.
19. Zisser H: Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care 2008;31:238-239.